- Gilead and Merck provide HIV data; Dimension Capital announces $800M fundGilead and Merck’s HIV data: The duo will present more detailed results of the Phase 3 trials of their once-weekly oral HIV treatment regimen at AIDS 2026, one of the largest ...Endpoints · 3d ago↗ source
- Agios’ second shot at sickle cell disease falls shortAgios said it is dropping a next-generation sickle cell disease drug after lackluster results from a mid-stage trial. The drug, known as tebapivat, represented Agios’ second shot at the disease,…Endpoints · 3d ago↗ source
- Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’<p>The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.</p>